[Sentinel lymph node mapping in non-small cell lung cancer].
Although identification of sentinel lymph nodes (SLN) with dye or radioisotope tracers has become a standard of care in both breast cancer and melanoma, it remains investigational in patients with lung cancer. SLN mapping has been performed in non-small cell lung cancer patients using isosulfan blue and radioisotope. The radioisotope method of SLN mapping appears to be more accurate than the dye technique in lung cancer patients. Several reports have demonstrated the feasibility of identifying the first site of potential nodal metastases of NSCLC. Furthermore, accurate sentinel node identification allows pathologists to focus on examinations with sensitive techniques to validate the SLN and to identify the presence of skip metastasis.
Okunaka
Tetsuaya
T
Pulmonary Disease Center, Sanno Hospital, International University of Health and Welfare, Tokyo, Japan.
Kato
Harubumi
H
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology*; D006801:Humans; D007530:Isoflurane; D008175:Lung Neoplasms / Q000473:pathology*; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*
D007530:Isoflurane